GallagherJC, RouseHM. Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother2008; 42:1188–94. Epub 10 Jul 2008. DOI 10.1345/aph.1L171
2.
PasteránF, RapoportM, PetroniAEmergence of PER-2 and VEB-1a 73 in Acinetobacter baumannii strains in the Americas. Antimicrob Agents Chemother2006; 50: 3222–4.
3.
CurcioD, FernandezF, DuretF.Initial use of tigecycline in Argentina. Rev Chilena Infectol2007; 24:497–9. Epub 13 Dec 2007.
4.
SahmDF, DowzickyMJ, DraghiDCSurveillance of tigecycline activity; discordance between national profiles associated with testing protocols and methods. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.American Society for Microbiology, Washington, DC, 2006:155.
5.
PillarCM, DraghiDC, DowzickyMJ, SahmDF. In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and E-test. J Clin Microbiol2008; 46:2862–7. Epub 2 Jul 2008.
6.
HigginsPG, WisplinghoffH, StefanikD, SeifertH.Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii.J Antimicrob Chemother2004; 54:821–3.
7.
MagnetS, CourvalinP, LambertT.Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother2001; 45: 3375–80.
8.
RaymondDP, PelletierSJ, CrabtreeTD, EvansHL, PruettTL, SawyerRG. Impact of antibiotic-resistant gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med2003; 31: 1035–41.
9.
RodvoldKA, GotfriedMH, CwikM, Korth-BradleyJM, DukartG, Ellis-GrosseEI. Serum, tissue and body fluid concentrations of tigecycline after a single 100-mg dose. J Antimicrob Chemother2006; 58: 1221–9.
10.
RelloJ.Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother2005; 17(suppl 1):12–22.
